• Doximity recently faced weaker sentiment as analysts highlighted an expected quarterly EPS decline alongside only modest revenue growth, amid a Zacks Rank of #5 (Strong Sell) and a discounted Forward P/E versus its industry.
• This combination of earnings concerns and valuation discount suggests investors are reassessing how the market is pricing Doximity’s current risks and strengths.
• Next, we'll explore how expectations for a quarterly EPS decline could influence Doximity's existing investment narrative built around AI and healthcare workflows.

Find 44 companies with promising cash flow potential yet trading below their fair value.

Doximity Investment Narrative Recap

To own Doximity, you need to believe its clinician network and AI tools can stay essential to healthcare workflows while translating usage into durable profits. The latest expectation for a quarterly EPS decline, despite modest revenue growth, mainly sharpens attention on execution: the key near term catalyst is proving AI and workflow products can support earnings, and the biggest risk is that monetization or pharma budgets soften enough to keep EPS under pressure. So far, this news does not appear to fundamentally alter that equation.

The most relevant recent update is Doximity’s new guidance for fiscal Q1 2026 and fiscal 2027, which frames how much earnings room the company has as sentiment weakens. With revenue projected at US$151 million to US$152 million for Q1 and US$664 million to US$676 million for fiscal 2027, investors can now compare these targets with the expected EPS decline and ask whether AI driven products and broader client demand are progressing fast enough to offset rising costs and regulatory or budget risks.

Yet, against this cautious backdrop, investors should be aware that the real risk may lie in how quickly Doximity can convert AI usage into paid value...

Doximity’s narrative projects $769.1 million revenue and $212.2 million earnings by 2029. This requires 6.0% yearly revenue growth and about a $16.1 million earnings increase from $196.1 million today.

Uncover how Doximity's forecasts yield a $25.42 fair value, a 22% upside to its current price.

Exploring Other Perspectives

Before this EPS concern, the most optimistic analysts were modeling revenue of about US$820 million by 2029, yet today’s weaker sentiment and earnings wobble show how quickly expectations can shift.

Explore 4 other fair value estimates on Doximity - why the stock might be worth as much as 64% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Doximity research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Doximity's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.